Supernus settles Oxtellar XR patent litigation with Apotex; generic entry allowed Sep 1, 2024

SUPERNUS PHARMACEUTICALS, INC.

Settlement resolves patent litigation with Apotex over generic Oxtellar XR (oxcarbazepine ER).
Apotex granted license to market generic version in U.S. beginning September 1, 2024.
Supernus retains right to market an authorized generic product itself or through third parties.
All claims and counter-claims in the patent litigation will be dismissed.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. entered into Settlement and License Agreements with Apotex Inc. and Apotex Corp. (collectively, "Apotex") (effective 2023-06-21).

Action: entry
Agreement: settlement
Counterparty: Apotex Inc. and Apotex Corp. (collectively, "Apotex")
Effective: 2023-06-21

Exact text from the filing

On June 21, 2023, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") entered into Settlement and License Agreements (the "Agreements) with Apotex Inc. and Apotex Corp. (collectively, "Apotex"), to settle ongoing patent litigation regarding Apotex's filing of an Abbreviated New Drug Application ("ANDA") seeking approval to market a generic version of the Company's Oxtellar XR ® (oxcarbazepine) extended-release tablets.

View on SEC.gov

Browse all material agreements →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.